New advancements, including automation, aim to fast-forward spatial biology SOUTH SAN FRANCISCO, Calif. , April 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced the
SOUTH SAN FRANCISCO, Calif. , April 03, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that it has entered into a multi-year engagement with global biopharmaceutical company
SOUTH SAN FRANCISCO, Calif. , March 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding shares of its Series B Convertible Preferred Stock (the “Series B Preferred”) for shares of common stock
Achieved FY2023 core financial objectives, delivering substantial ongoing reductions in expenses and cash burn while expanding revenue and gross margins Completed merger with SomaLogic, activating strategy to build scaled leader in life sciences tools and services Combined pro forma revenue for
SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – and Next Gen Diagnostics announce the execution of a long-term agreement aimed at revolutionizing the
SOUTH SAN FRANCISCO, Calif. , Feb. 22, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that management will participate in the following investor conferences: TD Cowen’s 44th
SOUTH SAN FRANCISCO, Calif. , Feb. 14, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that it will report fourth quarter and full year 2023 financial results on Wednesday,
Increasing access to Imaging Mass Cytometry in pharmaceutical and clinical research settings SOUTH SAN FRANCISCO, Calif. , Feb. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today
Achieving scale with pro forma full year 2023 revenue of approximately $192 million SOUTH SAN FRANCISCO, Calif. , Jan. 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB) ( Standard BioTools or the Company), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in
Establishes Leading Platform of Complementary Multi-omic Technologies with Enhanced Scale and Commercial Reach; Strengthened Balance Sheet to Self-Fund Future Growth Initiatives SOUTH SAN FRANCISCO, Calif. , Jan. 05, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc.
